Abstract
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.
Keywords
ValsartanMedicineHeart failureAngiotensin receptorAngiotensin IIRandomized controlled trialCardiologyRenin–angiotensin systemInternal medicinePharmacologyReceptorBlood pressure
Affiliated Institutions
Related Publications
The CARE‐HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end‐points
Abstract Background: Cardiac resynchronisation is a promising new intervention for patients with heart failure, left ventricular systolic dysfunction and ventricular dyssynchron...
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction
Background— Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF det...
Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGM‐HF</scp>)
Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global ...
A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mo...
Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure
In selected patients with heart failure, cardiac resynchronization therapy improves functional and hemodynamic status, reduces heart failure hospitalizations, and reduces all-ca...
Publication Info
- Year
- 2001
- Type
- article
- Volume
- 345
- Issue
- 23
- Pages
- 1667-1675
- Citations
- 3079
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
3079
OpenAlex
Cite This
Jay N. Cohn,
Gianni Tognoni
(2001).
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure.
New England Journal of Medicine
, 345
(23)
, 1667-1675.
https://doi.org/10.1056/nejmoa010713
Identifiers
- DOI
- 10.1056/nejmoa010713